Novo Nordisk is rated as a Buy compared to Eli Lilly because it trades at a significant valuation discount of about 26% to its big pharma peers despite having similar growth rates and a strong dividend yield. The stock is priced at roughly 11.2 times its projected 2027 earnings, offering potential annual returns of around 10% if current valuations and yields hold. Key risks include potential earnings drops after 2030, pipeline challenges, and price declines beyond the expected 10% annual decrease. A near-term catalyst is the US decision on CagriSema expected in Q4 2026, which could impact the stock's outlook.
As of Oct 08, 2026 10:41 WIB, Novo Nordisk trades at USD 38.25 on Pluang with a dividend yield of 4.79%, reflecting its appeal despite a high sell order activity of 85%. Eli Lilly is priced much higher at USD 1,188.14 with a lower dividend yield of 0.6%, and a more balanced order activity of 59% sell and 41% buy. The typical hold time for Novo Nordisk on Pluang is 116 days, longer than Eli Lilly's 93 days, indicating different investor engagement levels.
